Acupuncture Feasibility Trial for Dyspnea in Lung Cancer
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Ability to understand written English -Willingness to adhere to all study-related procedures
- Diagnosis of Lung Cancer (Non small cell and small cell both eligible)
- Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level)
- ...
- Ability to understand written English -Willingness to adhere to all study-related procedures
- Diagnosis of Lung Cancer (Non small cell and small cell both eligible)
- Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level)
- Age 18 years old
- ECOG Performance Status 1-3
- Completion of concurrent CRT at least 6 months prior to randomization.
Exclusion Criteria
- Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL)
- Surgical resection of this LC (lobectomy or pneumonectomy)
- Current bleeding disorder by history
- ...
- Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL)
- Surgical resection of this LC (lobectomy or pneumonectomy)
- Current bleeding disorder by history
- Current receipt of therapy for treatment related pneumonitis for 3 weeks.
- Life expectancy of 12 weeks, as assessed by primary oncologist
Summary
- Conditions
- Dyspnea
- Lung Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Ability to understand written English -Willingness to adhere to all study-related procedures
- Diagnosis of Lung Cancer (Non small cell and small cell both eligible)
- Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level)
- ...
- Ability to understand written English -Willingness to adhere to all study-related procedures
- Diagnosis of Lung Cancer (Non small cell and small cell both eligible)
- Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level)
- Age 18 years old
- ECOG Performance Status 1-3
- Completion of concurrent CRT at least 6 months prior to randomization.
Exclusion Criteria
- Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL)
- Surgical resection of this LC (lobectomy or pneumonectomy)
- Current bleeding disorder by history
- ...
- Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL)
- Surgical resection of this LC (lobectomy or pneumonectomy)
- Current bleeding disorder by history
- Current receipt of therapy for treatment related pneumonitis for 3 weeks.
- Life expectancy of 12 weeks, as assessed by primary oncologist
Tracking Information
- NCT #
- NCT02094950
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Joshua Bauml, MD Abramson Cancer Center of the University of Pennsylvania
- Joshua Bauml, MD Abramson Cancer Center of the University of Pennsylvania